There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nektar Therapeutics (NKTR) and Nkarta (NKTX) with bullish sentiments.
Nektar Therapeutics (NKTR)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Nektar Therapeutics, with a price target of $35.00. The company’s shares closed last Thursday at $18.52.
According to TipRanks.com, Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.9% and a 30.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Xeris Pharmaceuticals, and Magenta Therapeutics.
Currently, the analyst consensus on Nektar Therapeutics is a Moderate Buy with an average price target of $27.33.
See today’s analyst top recommended stocks >>
Nkarta (NKTX)
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Nkarta, with a price target of $81.00. The company’s shares closed last Thursday at $25.92, close to its 52-week low of $22.46.
According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -9.1% and a 40.8% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.
Currently, the analyst consensus on Nkarta is a Strong Buy with an average price target of $81.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
